Pioneering bone marrow transplantation – Led by Nobel Prize recipient Dr. E. Donnall Thomas, Fred Hutch researchers have transformed bone marrow transplantation into standard treatment for leukemia and other blood cancers. The procedure is widely recognized as one of the greatest achievements in cancer treatment and has saved the lives of hundreds of thousands of patients. Learn more >
Making transplantation less toxic – Dr. David Maloney has been leading clinical trials that investigate how combining lower-intensity radiation conditioning with an infusion of donated stem cells can effectively treat CLL patients.
Developing targeted radiotherapy – Dr. Johnnie Orozco is working to define future therapeutic interventions to improve outcomes for patients with cancers of the blood. research will test the potential of using targeted radioactive molecules — instead of highly toxic full-body irradiation — to prepare the body to receive a stem cell transplant. By targeting radioactive isotopes to the bone marrow only, he hopes to lessen some of the toxicity associated with pre-transplant conditioning.Learn more >
Promising immunotherapy for high-risk leukemia - Dr. Cameron Turtle led an early-phase trial where participants' T cells were removed from their blood and genetically engineered in a lab at Fred Hutch to produce an artificial receptor, called a CAR, or chimeric antigen receptor, that empowered them to recognize and destroy cancer cells bearing a target molecule called CD19. Most of the patients enrolled in this small, early-phase trial, saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells.
Learn more >
Dr. David Maloney is the medical director for cellular immunotherapy at Fred Hutch and the Immunotherapy Clinic at Seattle Cancer Care Alliance.